TWEETS by @pharma_BI and @AVIVA1950 at #IESYMPOSIUM – @kochinstitute 2019 #Immune #Engineering #Symposium, 1/28/2019 – 1/29/2019
Real Time Press Coverage: Aviva Lev-Ari, PhD, RN
2.1.3.4 TWEETS by @pharma_BI and @AVIVA1950 at #IESYMPOSIUM – @kochinstitute 2019 #Immune #Engineering #Symposium, 1/28/2019 – 1/29/2019, Volume 2 (Volume Two: Latest in Genomics Methodologies for Therapeutics: Gene Editing, NGS and BioInformatics, Simulations and the Genome Ontology), Part 2: CRISPR for Gene Editing and DNA Repair
eProceedings for Day 1 and Day 2
LIVE Day One – Koch Institute 2019 Immune Engineering Symposium, January 28, 2019, Kresge Auditorium, MIT
LIVE Day Two – Koch Institute 2019 Immune Engineering Symposium, January 29, 2019, Kresge Auditorium, MIT
-
AMAZING Conference I covered in Real Time
#Immune#Engineering
-
AMAZING Conference I covered in Real Time
-
LIVE Day One – e-Proceedings
#IESYMPOSIUM@pharma_BI@AVIVA1950@KochInstitute 2019#Immune#Engineering#Symposium, January 28, 2019, Kresge Auditorium, MIT https://pharmaceuticalintelligence.com/2019/01/28/live-day-one-koch-institute-2019-immune-engineering-symposium-january-28-2019-kresge-auditorium-mit/ … via@Pharma_BILIVE Day Two – Koch Institute 2019 Immune Engineering Symposium, January 29, 2019, Kresge Auditorium, MIT http://pharmaceuticalintelligence.com/2019/01/29/live-day-two-koch-institute-2019-immune-engineering-symposium-january-29-2019-kresge-auditorium-mit/ …
-
#IESYMPOSIUM@pharma_BI@AVIVA1950 Aviv Regev@kochinstitute Melanoma: malignant cells with resistance in cold niches in situ cells express the resistance program pre-treatment: resistance UP – cold Predict checkpoint immunotherapy outcomes CDK4/6 abemaciclib in cell lines -
#IESYMPOSIUM@pharma_BI@AVIVA1950 Aviv Regev,@broadinstitute@kochinstitute#Cell#atlases a#Cancer cell-cell interactions from variations across individuals Most UC-risk genes are cell type specificVariation – epithelial cell signature – organize US GWAS into cell type spec -
#IESYMPOSIUM@pharma_BI@AVIVA1950 Diane Mathis@HMS Age-dependent Treg and mSC changes – Linear with increase in age Sex-dependent Treg and mSC changes – Female Treg loss in cases of Obesity leading to fibrosis Treg keep IL-33-Producing mSCs under rein Lean tissue/Obese tissue -
#IESYMPOSIUM@pharma_BI@AVIVA1950 Martin LaFleur@HMS Loss of Ptpn2 enhances CD8+ T cell responses to LCMV and Tumors PTpn2 deletion in the immune system enhanced tumor immunity CHIME enables in vivo screening -
#IESYMPOSIUM@pharma_BI@AVIVA1950 Alex Shalek@MIT@kochinstitute Identifying and rationally modulating cellular drivers of enhanced immunity T Cells, Clusters Expression of Peak and Memory Immunotherapy- Identifying Dendritic cells enhanced in HIV-1 Elite Controllers -
-
You Retweeted
Onward: our own Michael Birnbaum, who assures us that if you feel like you’re an immunoengineer, then you ARE one!
@kochinstitute -
#IESYMPOSIUM@pharma_BI@AVIVA1950 Glenn Dranoff@Novartis Adenosine level in blood or tissue very difficult to measure in blood even more than in tissue – NIR178 + PDR 001 Monotherapy (NIR178) combine with PD receptor blockage (PDR) show benefit A alone vs A+B in Clinical trial -
#IESYMPOSIUM@pharma_BI@AVIVA1950 Glenn Dranoff@Novartis PD-L1 blockade elicits responses in some patients: soft part sarcoma LAG-3 combined with PD-1 – human peripheral blood tumor TIM-3 key regulator of T cell and Myeloid cell function: correlates in the TCGA DB myeloid -
#IESYMPOSIUM@pharma_BI@AVIVA1950 Glenn Dranoff@Novartis Institute for Biomedical Research#Mechnism of#protective#tumor#immunity Neurologic toxicities of CART t IL-6 activation AML – complete response – weekly dose of XmAb CD123X CD3 bispecific antibody anti tumor effect -
#IESYMPOSIUM@pharma_BI@AVIVA1950@michaelbirnbaum@MIT@kochinstitute#repertoire of protective#tumor#immunity HLA-DR4 effects outside of “peptide anchor” residues Class I MHC – HLA-E down regulate T and NK cells Receptor Binding: Positional preferences noted for NKG2A -
#IESYMPOSIUM@pharma_BI@AVIVA1950 Yvonne Chen@UCLA Activation of t Cell use CAR t Engineer CAR-T to respond to soluble form of antigens: CD19 CAR Responds to soluble CD19 GFP MCAR responds to Dimeric GFP “Tumor microenvironment is a scary place” -
#IESYMPOSIUM@pharma_BI@AVIVA1950 Yvonne Chen@UCLA Do we need a ligand to be a dimers? Co-expressed second-generation TGF-beta signaling
-
#IESYMPOSIUM@pharma_BI@AVIVA1950 Yvonne Chen@UCLA “Engineering smarter and stronger T cells for cancer immunotherapy” OR-Gate cause no relapse – Probing limits of modularity in CAR Design Bispecific CARs are superior to DualCAR: One vs DualCAR (some remained single CAR) -
You Retweeted
Ending the 1st session is Cathy Wu of
@DanaFarber detailing some amazing work on vaccination strategies for melanoma and glioblastoma patients. They use long peptides engineered from tumor sequencing data.#iesymposium -
You Retweeted
Some fancy imaging: Duggan gives a nice demo of how dSTORM imaging works using a micropatterend image of Kennedy Institute for Rheumatology! yay!
#iesymposium -
You Retweeted
Lots of interesting talks in the second session of the
#iesymposium – effects of lymphoangiogenesis on anti-tumor immune responses, nanoparticle based strategies to improve bNAbs titers/affinity for HIV therapy, and IAPi cancer immunotherapy -
You Retweeted
Looking forward to another day of the
#iesymposium. One more highlight from yesterday –@nm0min from our own lab showcased her work developing cytokine fusions that bind to collagen, boosting efficacy while drastically reducing toxicities
-
You Retweeted
Members of our cell therapy team were down the street today at neighboring
@MIT for the#iesymposium presented by@kochinstitute.#CRISPR#genomeediting
-
You Retweeted
He could have fooled me that he is, in fact, an immunologist!
-
-
You Retweeted
I absolutely LOVE this essay. “Why geneticists stole cancer research even though cancer is primarily a signaling disease”
-
You RetweetedMore
Come and say Hi! ACIR will be back tomorrow at the Immune Engineering Symposium at MIT. Learn more at http://ow.ly/gk9430ns0QX .
#iesymposium@kochinstitute. And stay tuned to read our summary of the talks on Feb 6.#subscribe#newsletter#IO#free
-
#IESYMPOSIUM@pharma_BI@AVIVA1950 Facundo Batista @MGH#Vaccine ##evaluation in#humanized#mousemodels BG18 Germline Heavy CHain (BG18-gH) High-mannose patch – mice exhibit normal B cell development B cells from naive human germline BG18-gH bind to GT2 immunogen -
#IESYMPOSIUM@pharma_BI@AVIVA1950 Preeti Sharma, U Illinois T cell receptor and CAR-T engineering TCR engineering for Targeting glycosylated cancer antigens Nornal glycosylation vs Aberrant Engineering 237-CARs libraries with conjugated (Tn-OTS8) against Tn-antigend In vitro -
#IESYMPOSIUM@pharma_BI@AVIVA1950 Bryan Bryson@MIT Loss of polarization potential: scRNAseq reveals transcriptional differences Thioredoxin facilitates immune response to Mtb is a marker of an inflammatory macrophage state functional spectrum of human microphages -
#IESYMPOSIUM@pharma_BI@AVIVA1950 Bryan Bryson@MIT macrophage axis in Mycobacterium tuberculosis Building “libraries” – surface marker analysis of Microphages Polarized macrophages are functionally different quant and qual differences History of GM-CSF suppresses IL-10 -
#IESYMPOSIUM@pharma_BI@AVIVA1950 Jamie Spangler John Hopkins University “Reprogramming anti-cancer immunity RESPONSE through molecular engineering” De novo IL-2 potetiator in therapeutic superior to the natural cytokine by molecular engineering mimicking other cytokines -
#IESYMPOSIUM@pharma_BI@AVIVA1950 Jamie Spangler@JHU JES6-1 Immunocytokine – inhibiting melanoma Engineering a Treg cell-biased immunocytokine double mutant immunocytokine shows enhanced IL-2Ralpha exchange Affinity De Novo design of a hyper-stable, effector biased IL-2 -
#Cardiovascular#Diseases, Volume Six:#Interventional#Cardiology for#disease#diagnosis and#Cardiac#Surgery for#Condition#Treatment. On com since 12/24/2018 https://lnkd.in/e_CTb4R@Pharma_BI@AVIVA1950 -
#Cardiovascular#Diseases, Volume Five:#PharmacologicalAgents in#Treatment of Cardiovascular Diseases. On com since 12/23/2018 https://lnkd.in/e3r87cQ@Pharma_BI@AVIVA1950 -
#Cardiovascular#Diseases, Volume Four:#Regenerative and#Translational#medicine : The#Therapeutics#Promise for Cardiovascular Diseases. On com since 12/26/2015 https://lnkd.in/dwqM3K3@Pharma_BI@AVIVA1950 -
#Cardiovascular#Diseases, Volume Three:#Etiologies of#Cardiovascular Diseases:#Epigenetics,#Genetics and#Genomics. On com since 11/29/2015 https://lnkd.in/ecp5mrA@Pharma_BI@AVIVA1950 -
#Cardiovascular#Diseases, Volume Two: Cardiovascular#Original#Research: Cases in#Methodology Design for#Content Co-Curation. On com since 11/30/2015 https://lnkd.in/ekbuNZ3@Pharma_BI@AVIVA1950 -
#Cardiovascular#Diseases, Volume One:#Perspectives on#Nitric#Oxide in#Disease#Mechanisms. On com since 6/21/2013 https://lnkd.in/8DANfq@pharma_BI@AVIVA1950 -
#IESYMPOSIUM@pharma_BI@AVIVA1950 eProceeding LIVE Day One@KochInstitute@MIT 2019#Immune#Engineering#Symposium, January 28, 2019, Kresge Auditorium, MIT https://pharmaceuticalintelligence.com/2019/01/28/live-day-one-koch-institute-2019-immune-engineering-symposium-january-28-2019-kresge-auditorium-mit/ … via@Pharma_BI -
#IESYMPOSIUM@pharma_BI@AVIVA1950 Michael Dustin@UniofOxford ESCRT pathway associated with synaptic ectosomes Locatization, Microscopy Cytotoxic T cell granules CTLs release extracellular vescicles similar to T Helper with perforin and granzyme – CTL vesicles kill targets -
#IESYMPOSIUM@pharma_BI@AVIVA1950 Michael Dustin@Oxford Delivery of T cell Effector function through extracellular vesicles Synaptic ectosome biogenisis Model: T cells: DOpamine cascade in germinal cell delivered to synaptic cleft – Effector CD40 – Transfer is cooperative -
#IESYMPOSIUM@pharma_BI@AVIVA1950 Michael Dustin@Oxford Delivery of T cell Effector function through extracellular vesicles Laterally mobile ligands track receptor interaction ICAM-1 Signaling of synapse – Sustain signaling by transient in microclusters TCR related Invadipodia -
#IESYMPOSIUM@pharma_BI@AVIVA1950 Mikael Pittet @MGH Myeloid Cells in Cancer Indirect mechanism AFTER a-PD-1 Treatment IFN-gamma Sensing Fosters IL-12 & therapeutic Responses aPD-1-Mediated Activation of Tumor Immunity – Direct activation and the ‘Licensing’ Model -
#IESYMPOSIUM@pharma_BI@AVIVA1950 Stefani Spranger@MIT KI Response to checkpoint blockade Non-T cell-inflamed – is LACK OF T CELL INFILTRATION Tumor CD103 dendritic cells – Tumor-residing Batf3-drivenCD103 Tumor-intrinsic Beta-catenin mediates lack of T cell infiltration -
#IESYMPOSIUM@pharma_BI@AVIVA1950 Max Krummel@UCSF Gene expression association between two genes:#NK and#cDC1 numbers are tightly linked to response to checkpoint blockage IMMUNE “ACCOMODATION” ARCHYTYPES: MYELOID TUNING OF ARCHITYPES Myeloid function and composition -
#IESYMPOSIUM@pharma_BI@AVIVA1950 Noor Momin, MIT Lumican-cytokines improve control of distant lesions – Lumican-fusion potentiates systemic anti-tumor immunityTranslate Tweet
-
#IESYMPOSIUM@pharma_BI@AVIVA1950 Noor Momin, MIT Lumican fusion to IL-2 improves treatment efficacy reduce toxicity – Anti-TAA mAb – TA99 vs IL-2 Best efficacy and least toxicity in Lumican-MSA-IL-2 vs MSA-IL2 Lumican synergy with CAR-T -
You Retweeted
excited to attend the
@kochinstitute@MIT immune engineering symposium#iesymposium this week! find me there to chat about@CellCellPress and whether your paper could be a good fit for us!
-
You Retweeted
Bob Schreiber and Tyler Jacks kicked off the
#iesymposium with 2 great talks on the role of Class I and Class II neo-Ag in tumor immunogenicity and how the tumor microenvironment alters T cell responsiveness to tumors in vivo -
You Retweeted
Scott Wilson from
@UChicago gave a fantastic talk on glycopolymer conjugation to antigens to improve trafficking to HAPCs and enhanced tolerization in autoimmunity models. Excited to learn more about his work at his@MITChemE faculty talk!#iesymposium -
-
You Retweeted
Immune Engineering Symposium at MIT is underway!
#iesymposium@kochinstitute
-
You RetweetedMore
ACIR is excited to be covering the Immune Engineering Symposium at MIT on January 28-29. Learn more at http://ow.ly/gk9430ns0QX .
#iesymposium@kochinstitute
-
Tyler Jacks talk was outstanding, Needs be delivered A@TED TALKs, needs become contents in the curriculum of Cell Biology graduate seminar as an Online class. BRAVO
@pharma_BI@AVIVA1950
-
You Retweeted
Here we go!! Today and tomorrow the tippity top immunologists converge at
@MIT@kochinstitute#iesymposium
-
You Retweeted
Exciting start to this year’s Immune Engineering Symposium put on by
@kochinstitute at@MIT. A few highlights from the first section…#iesymposium -
#IESYMPOSIUM@pharma_BI@AVIVA1950 Stephanie Dougan (Dana-Farber Cancer Institute) Dept. Virology IAPi outperforms checkpoint blockade in T cell cold tumors reduction of tumor burden gencitabine cross-presenting DCs and CD8 T cells – T cell low 6694c2 -
#IESYMPOSIUM@pharma_BI@AVIVA1950 Darrell Irvine (MIT, Koch Institute; HHMI) Engineering follicle delivery through synthetic glycans: eOD-60mer nanoparticles vs Ferritin-trimer 8-mer (density dependent) -
#IESYMPOSIUM@pharma_BI@AVIVA1950 Darrell Irvine (MIT, Koch Institute; HHMI) GC targeting is dependent on complement component CIQ – activation: Mannose-binding lectins recognize eOD-60mer but not eOD monomer or trimers -
#IESYMPOSIUM@pharma_BI@AVIVA1950 Melody Swartz (University of Chicago) Lymphangiogenesis attractive to Native T cells, in VEGF-C tumors T cell homing inhibitors vs block T cell egress inhibitors – Immunotherapy induces T cell killing -
Paradigm shift
#antigens vs#neoantigens#IESYMPOSIUM@pharma_BI@AVIVA1950
-
#IESYMPOSIUM@pharma_BI@AVIVA1950 Cathy Wu @MGH breakthrough for Brain Tumor#vaccine based neoantigen-specific T cell at intracranial site Single cells brain tissue vs single cells from neoantigen specific T cells – intratumoral neoantigen-specific T cells: mutARGAP35-spacific -
#IESYMPOSIUM@pharma_BI@AVIVA1950 Cathy Wu (Massachusetts General Hospital) – CoFounder of NEON Enduring complete radiographic responses after#Neovax + alpha-PD-1 treatment (anti-PD-1) NeoVax vs IVAC Mutanome for melanoma and Glioblastoma clinical trials -
#IESYMPOSIUM@pharma_BI@AVIVA1950@ScottWilson, U of Chicago IV INJECTION: OVAALBUMIN OVA-P(GALINAC), P(GLCNAC), SUPRESS T CELL RESPONSE#Glycoconjucates Abate T cells response – Reduced cytokine production & increased#T-regs -
#IESYMPOSIUM@pharma_BI@AVIVA1950@TylerJacks@MIT Interrogating markers of T cell dysfunction – chance biology of cells by CRISPR – EGR2 at 2 weeks dysfuntioning is reduced presence of EDR2 mutant class plays role in cell metabolism cell becomes functional regulator CD8 T cell -
#IESYMPOSIUM@pharma_BI@AVIVA1950 Bob Schreiber (Wash University of St. Louis) Optimal CD8+ T cells mediated#immuneresponses to T3#sarcomas require CD4+ T#cell help
2012pharmaceutical
Amandeep Kaur
Aashir Awan, Phd
Abhisar Anand
Adina Hazan
Alan F. Kaul, PharmD., MS, MBA, FCCP
alexcrystal6
anamikasarkar
apreconasia
aptubman
Arav Gandhi
aviralvatsa
David Orchard-Webb, PhD
danutdaagmailcom
Demet Sag, Ph.D., CRA, GCP
Dror Nir
dsmolyar
Ethan Coomber
evelinacohn
Gail S Thornton
Irina Robu
jayzmit48
jdpmd
jshertok
kellyperlman
Ed Kislauskis
larryhbern
Madison Davis
marzankhan
megbaker58
ofermar2020
Dr. Pati
pkandala
ritusaxena
Rick Mandahl
sjwilliamspa
Srinivas Sriram
stuartlpbi
Dr. Sudipta Saha
tildabarliya
zraviv06
zs22
Leave a Reply